Skip to main content

Lexicon Pharmaceuticals, Inc.

LXRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001062822

No open-market purchases or sales by Lexicon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 149 institutions reported holding it in 13F filings for Q2 2026, worth $875.1M in total; no superinvestor holds it.

Holders of 5% or more of LXRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lexicon Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of LXRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Invus Global Management, LLC13D/A39.40%175.2M shares+3.20 ppfrom 36.20%Feb 2, 20262 filingsMay 8, 2026SEC
FMR LLC13G/A11.70%51.8M shares+1.20 ppfrom 10.50%Jan 11, 20215 filingsAug 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

13 Schedule 13D and 13G filings on Lexicon Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LXRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 6, 202610:31 AM ETFMR LLCand 1 other13G/A11.70%51.8M shares+1.20 ppfrom 10.50%Jun 30, 2026SEC
May 8, 20269:42 PM ETInvus Global Management, LLCand 17 others13D/A39.40%175.2M shares+3.20 ppfrom 36.20%Apr 30, 2026SEC
Feb 2, 20269:54 PM ETInvus Global Management, LLCand 17 others13D/A36.20%154.7M shares–Jan 29, 2026SEC
Jul 8, 20259:07 AM ETFMR LLCand 1 other13G/A10.50%38.1M shares+0.90 ppfrom 9.60%Jun 30, 2025SEC
May 12, 202510:36 AM ETFMR LLCand 1 other13G/A9.60%34.5M shares–Mar 31, 2025SEC
Feb 14, 2023Biotechnology Value Fund L P13G/AOld format–––SEC
Aug 9, 2022Invus, L.P.13D/AOld format–––SEC
Aug 1, 2022Invus, L.P.13D/AOld format–––SEC
Feb 14, 2022Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Jan 21, 2021Invus, L.P.13D/AOld format–––SEC
Jan 11, 2021FMR LLC13G/AOld format–––SEC
Jan 5, 2021Invus, L.P.13D/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Lexicon Pharmaceuticals, Inc. shares.

No Form 144 notices for Lexicon Pharmaceuticals, Inc. are on file.